Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY,
January 4, 2024
Category: Press Releases
nCino to Participate in Upcoming Investor Conference
WILMINGTON, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in
January 4, 2024
Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing
Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale,
January 4, 2024
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455
January 4, 2024
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455
January 4, 2024
Zymeworks Announces Additional Leadership Appointments
Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted
January 4, 2024